top of page
Search

Rheum: Endo: MEN Syndromes (Type 1, 2A, 2B) for MRCP Part 1

TL;DR

Rheum: Endo: MEN Syndromes (Type 1, 2a, 2b) are high-yield endocrine topics in MRCP Part 1, focusing on tumour patterns, genetic mutations, and screening priorities. MEN1 involves the “3 Ps” (parathyroid, pancreas, pituitary), while MEN2 syndromes revolve around RET mutations and medullary thyroid carcinoma. The key to exam success is distinguishing MEN2A vs MEN2B and remembering management order (treat phaeochromocytoma first). Expect pattern-recognition MCQs with genetics and tumour associations.

Why this matters

Multiple Endocrine Neoplasia (MEN) syndromes are classic MRCP Part 1 questions because they test integration of endocrinology, oncology, and genetics. These conditions are not just memorisation topics—they assess your ability to recognise patterns quickly under exam pressure.

A strong grasp of MEN syndromes also strengthens your understanding of endocrine tumour screening and hereditary cancer syndromes. If you are building your core revision, start with the MRCP Part 1 overview:👉 https://www.crackmedicine.co.in/mrcp-part-1/


Core concepts you must know

MEN syndromes are autosomal dominant inherited disorders characterised by tumours in multiple endocrine glands. The three main types:

  • MEN1 (Wermer syndrome)

  • MEN2A (Sipple syndrome)

  • MEN2B

Each has:

  • A specific gene mutation

  • A predictable tumour pattern

  • Defined screening strategies


High-yield comparison table

Feature

MEN1

MEN2A

MEN2B

Gene

MEN1 (tumour suppressor)

RET proto-oncogene

RET proto-oncogene

Mutation type

Loss-of-function

Gain-of-function

Gain-of-function

Key tumours

Parathyroid, Pancreatic NETs, Pituitary

Medullary thyroid CA, Phaeochromocytoma, Parathyroid

Medullary thyroid CA, Phaeochromocytoma, Neuromas

Calcium

High

Mildly high

Normal

Unique feature

“3 Ps”

Hyperparathyroidism

Marfanoid habitus + mucosal neuromas

MEN1: The “3 Ps”

Key features

  • Parathyroid hyperplasia (most common initial presentation)

  • Pancreatic neuroendocrine tumours (NETs)

    • Gastrinoma → Zollinger–Ellison syndrome

    • Insulinoma

  • Pituitary adenoma

    • Prolactinoma most common

Exam pearls

  • Hypercalcaemia is often the first clue

  • Recurrent peptic ulcers → think gastrinoma

  • MEN1 gene = tumour suppressor gene mutation

MEN2A: The classic triad

Key features

  • Medullary thyroid carcinoma (MTC)

  • Phaeochromocytoma

  • Parathyroid hyperplasia

Exam pearls

  • Calcitonin is the tumour marker

  • RET mutation = gain-of-function

  • Always exclude/treat phaeochromocytoma before thyroid surgery

MEN2B: The aggressive variant

Key features

  • Early, aggressive medullary thyroid carcinoma

  • Phaeochromocytoma

  • Mucosal neuromas (lips, tongue)

  • Marfanoid habitus

Exam pearls

  • No hyperparathyroidism

  • Presents earlier than MEN2A

  • Requires early prophylactic thyroidectomy

The 5 most tested subtopics

  1. Genetics

    • MEN1 → tumour suppressor

    • MEN2 → RET proto-oncogene

  2. Tumour associations

    • MEN1 = 3 Ps

    • MEN2A = MTC + Phaeo + Parathyroid

    • MEN2B = MTC + Phaeo + Neuromas

  3. Biochemical markers

    • Calcitonin → MTC

    • Gastrin → gastrinoma

    • Prolactin → pituitary adenoma

  4. Screening strategies

    • Genetic testing in families

    • Early thyroidectomy in RET mutation

  5. Management order

    • Treat phaeochromocytoma first


High-yield revision list

  1. MEN1 = Parathyroid + Pancreas + Pituitary

  2. MEN2 = RET mutation

  3. MEN2A includes hyperparathyroidism

  4. MEN2B includes neuromas + marfanoid habitus

  5. Calcitonin = marker for medullary thyroid carcinoma

  6. Hypercalcaemia → think MEN1

  7. Gastrinoma → recurrent ulcers

  8. Always treat phaeochromocytoma first

  9. MEN1 = loss-of-function mutation

  10. MEN2 = gain-of-function mutation


Practical example (MCQ)

Question: A 26-year-old man presents with recurrent peptic ulcers and hypercalcaemia. His sister has a pituitary tumour. What is the most likely diagnosis?

A. MEN2AB. MEN2BC. MEN1D. Sporadic gastrinoma

Answer: C. MEN1

Explanation: This is the classic MEN1 pattern:

  • Hypercalcaemia → parathyroid involvement

  • Peptic ulcers → gastrinoma

  • Family history → pituitary tumour

Together, these form the “3 Ps” of MEN1.

👉 Practise similar questions here:


Common pitfalls

  • Confusing MEN2A and MEN2B (look for neuromas in MEN2B)

  • Forgetting MEN1 presents first with hyperparathyroidism

  • Missing the rule: phaeochromocytoma must be treated first

  • Assuming MEN2B has hyperparathyroidism (it does not)

  • Not recognising calcitonin as a key tumour marker


Practical study checklist

Use this checklist during revision:

  • □ Can I recall the MEN1 “3 Ps” instantly?

  • □ Do I know MEN2A vs MEN2B differences without hesitation?

  • □ Can I identify RET mutation syndromes?

  • □ Do I remember management order (phaeo first)?

  • □ Can I answer MCQs based on tumour combinations?

Medical student revising endocrine system diagrams for MEN syndromes MRCP Part 1 preparation

FAQs

1. What is the key difference between MEN2A and MEN2B?

MEN2B includes mucosal neuromas and marfanoid habitus, while MEN2A includes hyperparathyroidism. MEN2B is more aggressive and presents earlier.

2. Which MEN syndrome presents with hypercalcaemia first?

MEN1 typically presents with primary hyperparathyroidism, leading to hypercalcaemia.

3. Why treat phaeochromocytoma before thyroid surgery?

Untreated phaeochromocytoma can cause a life-threatening catecholamine surge during surgery.

4. What gene mutation is seen in MEN syndromes?

MEN1 involves a tumour suppressor gene mutation, while MEN2 involves activating RET proto-oncogene mutations.

5. What is the tumour marker for medullary thyroid carcinoma?

Calcitonin is used for diagnosis and monitoring of medullary thyroid carcinoma.


Call to action

MEN syndromes are pattern-recognition gold in MRCP Part 1. Focus on tumour clusters, genetics, and management priorities to maximise your score.

Strengthen your preparation:

For deeper endocrine revision, pair this with topics like thyroid malignancies and adrenal disorders from your lecture series:👉 https://www.crackmedicine.co.in/lectures/


Sources

 
 
 

Comments

bottom of page